Tauklarify imaging is a brain PET scan that helps identify tau tangles in cognitively impaired adults being evaluated for Alzheimer's disease in 2026. In pivotal studies it showed strong negative agreement and moderate to strong positive agreement, but a result alone does not diagnose or rule out Alzheimer's. Tau tangles are twisted clumps of tau protein that build up inside brain cells and disrupt memory circuits. Tauklarify uses florquinitau F 18 injection, formerly called MK-6240, which binds aggregated tau so tangles appear on PET.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What does the scan add to an Alzheimer's workup?
- How accurate is it?
- What are the key limits and evidence gaps?
- Who should not get it, and what should primary care patients do?
What does the scan add to an Alzheimer's workup?
Tauklarify is the second FDA-approved tau PET tracer, after Eli Lilly's Tauvid. It joins amyloid PET tracers, spinal fluid tests and blood tests used in dementia evaluation, according to NeurologyLive.
Its practical difference is sensitivity in the medial temporal lobe. According to the Lantheus Holdings announcement, Tauklarify can detect tangles isolated to that region, covering early Alzheimer stages where older tracer Tauvid is less sensitive.
How accurate is it?
In two pivotal studies with 617 patients and five blinded readers, positive agreement was 68%-88% and negative agreement was 93%-99%, according to reporting by Pharmacy Times. Readers agreed strongly with each other, with Fleiss kappa around 0.86-0.92.
That pattern means a negative scan is usually read the same way by different doctors. A positive scan is less consistent, so clinical context matters more when the scan lights up.
What are the key limits and evidence gaps?
Accuracy was established mainly by comparing amyloid-negative unimpaired people with amyloid-positive impaired patients. Performance may be lower in earlier or intermediate pathology, when tau burden is mixed or still spreading.
FDA labeling also sets a firm boundary: a negative scan does not exclude tau pathology and a positive scan does not confirm histopathologic disease. According to NeurologyLive's update, uncertain cases require additional evaluation rather than treatment based on PET alone.
Who should not get it, and what should primary care patients do?
Safety and effectiveness are not established for non-Alzheimer tau diseases such as progressive supranuclear palsy or corticobasal degeneration. Primary care should not use Tauklarify for undifferentiated parkinsonism or frontotemporal syndromes. If memory loss prompts a referral, ask these practical questions: In 1,734 subjects, headache occurred in 0.7% and nausea in 0.2%, but PET adds radiation burden, needs hydration and voiding, 7-day avoidance of CYP1A2 inducers and smoking, and a 4-hour lactation pause, according to reporting by Pharmacy Times.
- Am I cognitively impaired and being evaluated specifically for Alzheimer's?
- Will tau PET change the next step after cognition testing, amyloid testing and medical workup?
- Where is PET available, what radiation and preparation does it require, and who will explain an uncertain result?
You Might Also Like
- PrecivityAD2 and Younger-Onset Alzheimer’s Diagnosis in 2026: Accuracy, Limits, and Evidence Gaps for Primary Care Patients
- PrecivityAD2 as an Adjunct to a 2026 Alzheimer’s Assessment: Accuracy, Limits, and Evidence Gaps for Primary Care Patients
- FDA’s 2026 PrecivityAD2 Alzheimer’s Blood Test Clearance: Accuracy, Limits, and Evidence Gaps for Primary Care Patients
